249 related articles for article (PubMed ID: 18787018)
1. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.
Adams BD; Claffey KP; White BA
Endocrinology; 2009 Jan; 150(1):14-23. PubMed ID: 18787018
[TBL] [Abstract][Full Text] [Related]
2. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells.
Adams BD; Cowee DM; White BA
Mol Endocrinol; 2009 Aug; 23(8):1215-30. PubMed ID: 19423651
[TBL] [Abstract][Full Text] [Related]
3. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
4. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
5. Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation.
Conger AK; Martin EC; Yan TJ; Rhodes LV; Hoang VT; La J; Anbalagan M; Burks HE; Rowan BG; Nephew KP; Collins-Burow BM; Burow ME
Noncoding RNA; 2016 Sep; 2(3):. PubMed ID: 29657266
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks.
Banerjee S; Sengupta K; Saxena NK; Dhar K; Banerjee SK
Mol Cancer Res; 2005 Mar; 3(3):151-62. PubMed ID: 15798095
[TBL] [Abstract][Full Text] [Related]
7. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
[TBL] [Abstract][Full Text] [Related]
8. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
[TBL] [Abstract][Full Text] [Related]
9. Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells.
Bellissimo T; Tito C; Ganci F; Sacconi A; Masciarelli S; Di Martino G; Porta N; Cirenza M; Sorci M; De Angelis L; Rosa P; Calogero A; Fatica A; Petrozza V; Fontemaggi G; Blandino G; Fazi F
Cell Death Dis; 2019 Jan; 10(1):17. PubMed ID: 30622242
[TBL] [Abstract][Full Text] [Related]
10. Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
Song X; Wei Z; Shaikh ZA
Toxicol Appl Pharmacol; 2015 Aug; 287(1):26-34. PubMed ID: 26006730
[TBL] [Abstract][Full Text] [Related]
11. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
12. Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Padua MB; Bhat-Nakshatri P; Anjanappa M; Prasad MS; Hao Y; Rao X; Liu S; Wan J; Liu Y; McElyea K; Jacobsen M; Sandusky G; Althouse S; Perkins S; Nakshatri H
Breast Cancer Res; 2018 May; 20(1):35. PubMed ID: 29720215
[TBL] [Abstract][Full Text] [Related]
13. Prolyl 4-hydroxylation regulates Argonaute 2 stability.
Qi HH; Ongusaha PP; Myllyharju J; Cheng D; Pakkanen O; Shi Y; Lee SW; Peng J; Shi Y
Nature; 2008 Sep; 455(7211):421-4. PubMed ID: 18690212
[TBL] [Abstract][Full Text] [Related]
14. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
15. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells.
Albanito L; Sisci D; Aquila S; Brunelli E; Vivacqua A; Madeo A; Lappano R; Pandey DP; Picard D; Mauro L; Andò S; Maggiolini M
Endocrinology; 2008 Aug; 149(8):3799-808. PubMed ID: 18467441
[TBL] [Abstract][Full Text] [Related]
17. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer.
Wang J; Barnes RO; West NR; Olson M; Chu JE; Watson PH
Breast Cancer Res; 2008; 10(3):R51. PubMed ID: 18534028
[TBL] [Abstract][Full Text] [Related]
18. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
[TBL] [Abstract][Full Text] [Related]
19. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2016 Oct; 7(40):65602-65613. PubMed ID: 27564112
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
